Abstract. The ranking and prediction of novel therapeutic categories for existing drugs (drug repositioning) is a challenging computational problem involving the analysis of complex chemical and biological net-works. In this context we propose a novel semi-supervised learning prob-lem: ranking

Background. Drug treatment is becoming more expensive due to the increased cost for the introduction of new drugs, and there seems to be an uneven distribution of medication cost for different therapeutic categories. We hypothesized that the cost of new antimicrobial agents may differ from

therapeutic categories and age considerations

without solid scientific footing. This is the nature of the complaint addressed in this article, and the authors propose that these categories be reexamined using diagnostic conventions that already exist in the Diagnostic and Statistical Manual of Mental Disorders (4th ed., text rev.; DSM–IV–TR; American

categories which had highest sales. The selected brands were ranked in the order of their sale volume. Outcome: Percentage price variation between different fast moving brands in the therapeutic classes of Analgesics, Antiasthma, Antibiotics, Cardiovascular, , Antidiabetics, Antiulcer, Hypolipidemics

on its ability to inhibit apoptosis, the B-cell lymphoma/leukemia 2 (Bcl-2) protein family has garnered the most attention as a promising therapeutic target in cancer. Accordingly, efforts have lately been focused on the development of drugs targeting Bcl-2 proteins with considerable therapeutic success

The controversy over the prescription drug, alosetron, is examined in order to investigate what is permitted to count as ‘therapeutic advance ’ and ‘therapeutic breakthrough ’ within pharmaceutical innovation and regula-tion. It is argued that those official accounting categories can mask very

and target it for proteasomal degradation. IAPs are differentially expressed in tumor cells and have been targeted by several cancer therapeutic drugs that are currently in clinical trials. Here, we summarize the current knowledge on the role of IAPs in the regulation of cell migration and discuss

variable over time. A primary SB clinical diagnosis is made by evaluation of a patient’s history and a dental examination. Sleep studies are indicated to rule out anassociated sleep pathology, such as sleep-disordered breathing, and to evaluate sleep-state teeth grinding and arousals. Therapeutic

ABSTRACT: For the second time in the past ten years adverse reports in the lay press have questioned the safety of triazolam. Anecdotal reports of central nervous system adverse reactions can be separated into four general categories: (I) delirium in psychiatric patients; (2) delirium in geriatric